HTML Layer


An enzymatic solution for gluten-related disorders

We are healthier together


Working together to halt the first step of gluten intolerance

We are healthier together


At a human level.

We are healthier together

Medical Innovation

Identifying and creating therapies that address the first stage of Celiac Disease and Non-Celiac Gluten Sensitivity.

Enteralia is a healthcare and pharmaceutical company, founded by a multidisciplinary team of scientists and executives with a proven track record of delivering products to market. We are committed to pharmaceutical solutions that ameliorate the negative consequences of nutrient intolerances and sensitivities, specific to the gastrointestinal tract, such as Celiac Disease and Non-Celiac Gluten Sensitivity.

Our mission is to apply a proprietary enzymatic approach to alleviate the symptoms associated with gluten-related disorders.

By utilising novel approaches and technologies, as well as collaborating with universities, research organizations, and healthcare professionals, we strive to improve the lives of patients while ensuring the needs of our employees, partners, and investors are met.

The patients’ needs remain a north star for us, and we are thrilled to have found a potential answer for the hundreds of millions suffering from gluten related disorders.

Danilo Casadei Massari | Founder

Together we can address patient’s nutritional deficiencies through innovations that make their everyday lives better, whilst minimising potential side effects.

Research & Development

Our main product, E40, currently in development, has been designed to address unmet patient needs and significant market gaps.

Patients who are intolerant or sensitive to gluten can inadvertently consume gluten even when on a gluten-free diet. Our novel glutenase, E40 has been shown to break down the immunogenic peptides from the digestion of gluten that can make the lives of patients with Celiac Disease and Non-Celiac Gluten Sensitivity so uncomfortable and painful.

We’re committed to providing safe and efficacious solutions that halt the first step of the pathogenic cascade of Celiac Disease.

Maria Cristina Comelli | Director R&D